Replies to post #86494 on Biotech Values

[mcbio]

Re: ACHN @ JPM

If the results are good, I think ACHN will find a way to release the top-line data at the JPM conference—even if they do decide to run another dosing cohort. The corollary is that not releasing at least some top-line data at JPM ought to be interpreted as a negative signal.

I think that's a good thought and I hope I remember it early next year.